Engage Therapeutics is a clinical-stage biopharmaceutical company developing Staccato® alprazolam, a hand-held inhaled drug-device combination intended to stop acute epileptic seizures. The product leverages Alexza Pharmaceuticals' Staccato delivery technology combined with FDA-approved alprazolam and showed seizure cessation in under two minutes in a Phase 2a photosensitivity proof-of-concept study. Engage holds an exclusive license and supply agreement with Alexza and plans to pursue approval via the FDA’s 505(b)(2) pathway. The company intends to commence a Phase 2b clinical trial, with Dr. Jacqueline A. French as principal investigator. Engage aims to position Staccato alprazolam as an EpiPen®-like rescue treatment for people with uncontrolled seizures. The company is based in Summit, N.J., and recently closed a $23 million Series A to fund the Phase 2b program.

Total raised

$23M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2017